Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety of new P2Y12 inhibitors (ticagrelor and prasugrel) versus clopidogrel in diabetic patients with acute coronary syndromes

Next Previous
Trial Profile

Safety of new P2Y12 inhibitors (ticagrelor and prasugrel) versus clopidogrel in diabetic patients with acute coronary syndromes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prasugrel (Primary) ; Ticagrelor (Primary) ; Clopidogrel
  • Indications Acute coronary syndromes; Coronary artery disease; Peripheral arterial disorders; Stroke
  • Focus Adverse reactions
  • Acronyms ACHILLES

Most Recent Events

  • 08 Jan 2020 Results analyzing the clinical profile of acute coronary synrome and the efficacy and safety of novel oral P2Y12 inhibitors in current clinical practice patients discharged after an acute coronary syndrome published in the British Journal of Clinical Pharmacology
  • 03 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top